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a b s t r a c t
Sarcopenia is characterized by age-associated skeletal muscle atrophy and reduced muscle strength; cur-
rently, no pharmaceutical treatment is available. Go-sha-jinki-Gan (GJG) is a traditional Japanese herbal
medicine that is used to alleviate various age-related symptoms, especially motor disorders. Here, we inves-
tigated the effect of GJG on aging-associated skeletal muscle atrophy by using senescence-accelerated mice
(SAMP8). Immunohistochemical andwestern blotting analyses clearly showed that GJG signiﬁcantly reduced
the loss of skeletal muscle mass and ameliorated the increase in slow skeletal muscle ﬁbers in SAMP8 mice
compared to control mice. The expression levels of Akt and GSK-3β , the phosphorylation of FoxO4, and the
phosphorylations of AMPK andmitochondrial-related transcription factors such as PGC-1α were suppressed,
while the expression of MuRF1 increased in SAMP8 mice, but approximated that in senescence-accelerated
aging-resistant (SAMR1) mice after GJG treatment. We demonstrate for the ﬁrst time that GJG has a thera-
peutic effect against sarcopenia.
© 2015 The Authors. Published by Elsevier GmbH.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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MIntroduction
As mammals age, muscle mass and strength decrease progres-
sively, a phenomenon known as sarcopenia (Wickham et al. 1989).
Sarcopenia is characterized by the reduction in the size and number
of muscle ﬁbers, muscle mass, and the ratio of slow-twitch muscle
ﬁbers to fast-twitch muscle ﬁbers (Lexell et al. 1988). Sarcopenia is a
major determinant of the decline in physical function in older adults
(Cruz-Jentoft et al. 2010). Although some trials have aimed at re-
versing the reduction in muscle mass, there is currently no effective
pharmaceutical treatment for sarcopenia (Sayer et al. 2013). Multi-
ple factors appear to be involved in the development of sarcopenia:
changes in insulin-like growth factor (IGF-1), changes in the mito-
chondrial network, and chronic inﬂammation are followed by alter-
ations in signaling pathways in themuscle (Bonaldo and Sandri 2013).
IGF-1 activates phosphatidylinositol-3-kinase (PI3K), resulting in
Akt activation. Akt inhibits protein degradation by repressing the
forkhead box protein (FoxO) family, leading to expression of atrogin-
1/Muscle Atrophy F-box (MAFbx) and Muscle RING-Finger Protein-1
(MuRF1) (Brunet et al. 1999; Franke et al. 1997). Akt stimulates pro-∗ Corresponding author at: Department of Kampo Medicine, Osaka Univer-
sity Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
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0944-7113/© 2015 The Authors. Published by Elsevier GmbH. This is an open access article uein synthesis by regulating glycogen synthase kinase 3β (GSK3β)
Moule et al. 1997). It has been shown that lower plasma concen-
rations of IGF-1 and higher plasma concentrations of tumor necro-
is factor-alpha (TNF-α) are associated with lower muscle mass and
trength in the elderly (Donahue et al. 1990; Visser et al. 2002).
Go-sha-jinki-Gan (GJG) is a traditional Japanese herbal medicine
omposed of 10 herbal drugs in ﬁxed proportions (Usuki et al. 1991).
his medicine has been used to alleviate various types of age-related
onditions in the locomotor apparatus. Previous studies have not re-
orted any severe adverse effects of GJG in humans (Launer et al.
990). Despite the potential of GJG as an anti-aging drug, few stud-
es have clariﬁed its effect on senescent skeletal muscle. Therefore,
e investigated whether GJG can protect against sarcopenia by using
enescence-acceleratedmice (SAMP8), which exhibit several acceler-
ted aging characteristics, are widely used in aging research (Takeda
t al. 1997), and have been reported to bet a cost-effective model for
uscular aging studies (Derave et al. 2005). Here, we show that GJG
arkedly protects against sarcopenia in SAMP8 mice.
aterials and methods
reparation of GJG extract and animals
Spray-dried, water-extracted GJG powder was obtained from
sumura & Co. (Tokyo, Japan). GJGwas approved in 1986 as a drug fornder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Fig. 1. HPLC analysis of GJG.
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tlinical use by the JapaneseMinistry of Health, Labour andWelfare. It
s produced at the Shizuoka plant which meets Japanese pharmaceu-
ical GMP (good manufacturing practice). The local pharmaceutical
dministration of Shizuoka Prefecture assesses the GMP status of the
lant every 5 years. The plant has had permission for pharmaceutical
roduction for more than 30 years, and the production process has
eenwell validated. Since active substances are still ambiguous, qual-
ty control is conducted by quantitation of major components. In the
ase of GJG, paeoniﬂorin (moutan bark), loganin (Rehmannia root),
nd total alkaloids (processed aconite root) are chosen as marker
ompounds for quality control. Paeoniﬂorin, loganin, and total alka-
oids in 1 g of GJG extract powder used in our experiments were
.11, 1.58, and 0.11 mg, respectively. In 10 lots (a total of 20 lots)
roduced before and behind this lot, paeoniﬂorin, loganin, and total
lkaloids were within ± 10% of the range of this content, and quality
as managed satisfactorily. Other physicochemical properties, e.g.
oss on drying, water content, ash, heavy metals, etc., were also ex-
mined in all lots. GJG extract is listed in the Japanese Pharmacopeia,
nd the material used in this study met that description. The general
anufacturing procedure of GJG extract powder is as follows. Ten
inds of botanical raw materials are crushed and then weighed in
ccordance with the mixing ratio as shown in Table S1. The mixture
f botanical raw materials is extracted 12 times with ion-exchanged
ater for 60 min at 100 °C. The extract is centrifuged to obtain a
upernatant, which is then concentrated in vacuo. The concentrated
xtract solution is dried by a spray dryer. The standard yield of extract
owder is around 16% of the total weight of botanical rawmaterials. A
hree-dimensional high-performance liquid chromatography (HPLC)
roﬁle of a methanol solution of GJG was performed according to our
revious procedure (Hattori et al. 2010) and is shown in Fig. 1.D-HPLC analysis and LC/MS analysis of the crude drugs involved
n GJG are shown in Figs. S1–S3.
Seven-week-old male SAMP8 mice were purchased from SLC, Inc.
Shizuoka, Japan) and divided into 2 groups: those fed a normal
iet (powdered mouse food; Oriental Yeast Co. Ltd. (Tokyo, Japan;
8 + N group; n = 10)); and those fed a normal diet supplemented
ith 4% (w/w) GJG (P8 + GJG group; n = 10). As controls, 7-week-
ld male SAMR1 mice were purchased from SLC and also divided
nto 2 groups: those fed a normal diet (R + N group; n = 10) and
hose fed a normal diet supplemented with 4% (w/w) GJG (R + GJG
roup; n = 11). General conditions and body weight were recorded
or all mice. The housing care rules and experimental protocol were
arried out in accordance with the National Institutes of Health
uide for the Care and Use of Laboratory Animals, and the proto-
ols were approved by the Animal Care and Use Committee of Osaka
niversity.
mmunohistochemistry, histological analysis, and PAS staining
At 38 weeks, the mice were euthanized and tibiae were removed.
amples from 4 or 5 mice were photographed. Samples from 3 mice
ere ﬁxed in 10% formalin, and the other samples were frozen at
80 °C until required for use. Samples were embedded in paraf-
n. They were stained with hematoxylin and eosin (H&E) and the
oleus muscles were evaluated microscopically to conﬁrm the state
f the muscles. The area of a muscle ﬁber was measured by evalu-
ting 300 ﬁbers that were randomly selected using WinROOF soft-
are (Mitani-Corp, Fukui, Japan). For the sarco/endoplasmatic Ca2+-
ependent ATPase-driven pump 1 (SERCA1) gene expressed in fast-
witchmuscle (type II) ﬁbers (PeriasamyandKalyanasundaram2007),
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Fig. 2. GJG improved muscle ﬁber size. (a) Photographs of lower extremities. (b) H&E staining of the soleus muscles of the mice. The bar indicates 200 μm. Magniﬁcation: 100×.
(c) The area of muscle ﬁbers was measured. These data are expressed as means ± SD. ∗p < 0.0001 vs. P8 + N group (one-way ANOVA).
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panti- SERCA1 ATPase (AbcamCambridge,MA, USA)was visualized us-
ing 3,3-diaminobenzidine (DAB) with counterstaining by eosin. Fiber
type distribution as a percentage was calculated. Periodic acid-Schiff
(PAS) staining was performed using a PAS kit (Muto, Tokyo, Japan)
according to the manufacturer’s protocol.
ELISA and western blotting
We measured the sera of mice in duplicate using a mouse IGF-1
ELISA system (Abcam). The limit of sensitivity for IGF-1 was 2.74
pg/ml. The soleus muscles were homogenized and analyzed bymmunoblot analysis. We used the following antibodies: anti-
roponin T (fast skeletal muscle) was purchased from Abbiotec, LLC;
nti-troponin I (slow skeletal muscle) was purchased from Novus
iologicals, LLC; anti-PGC-1α was purchased from Calbiochem
Darmstadt, Germany); anti-GAPDH, anti-phospho-Akt (Thr308),
nti-phospho-Akt (Ser473), anti-phospho-GSK3-β , anti-GSK3-β ,
nti-phospho-FoxO4 (Ser193), anti-phospho-5′-AMP-activated pro-
ein kinase (AMPK) (Thr172), anti-AMPK-alpha, anti TNF-α, and anti-
kt were purchased from Cell Signaling Technology (Danvers, MA,
SA); and anti-FoxO4, anti-MAFbx, and anti-MuRF1 antibodies were
urchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
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Fig. 3. GJG normalized the imbalance of muscle ﬁber in SAMP8mice. (a) Immunohistochemical analysis of SERCA1 (fast skeletal muscle marker), visualized with DAB (brown) and
counterstainedwith hematoxylin. The bar indicates 200μm.Magniﬁcation: 200×. (b) The ratio of fast skeletalmuscle to the soleusmuscle. These data are expressed asmeans± SD.
∗p < 0.0001 vs. P8 + N group (one-way ANOVA). (c) Expression of troponin I (slow skeletal muscle marker), troponin T (fast skeletal muscle marker), PGC-1α, p-AMPK, and AMPK
as determined bywestern blotting analysis of the soleusmuscles. GAPDH is shown as a loading control. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
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otatistical analysis
Data are presented as means ± standard deviation values. Groups
ere comparedbyone-wayanalysis of variance (ANOVA).Differences
etween treatment groups were considered signiﬁcant at p < 0.05.
esults
JG suppressed the reduction in muscle ﬁber size in the soleus of
AMP8 mice
Nomice in the GJG group experienced unusual activity.Within the
ame strain, there was no signiﬁcant difference in weight regardless
f whether the mice were fed GJG. No signiﬁcant differences in food
ntake per day were found among these groups (P8 + N: 3.9 ± 0.7 g,8 + GJG: 3.8 ± 0.4 g, R + N: 3.8 ± 0.3 g: R + GJG: 3.7 ± 0.5 g). No
igniﬁcant differences in GJG intake per day were found between GJG
roups (P8 + GJG: 0.15 ± 0.02 g, R + GJG: 0.15 ± 0.02 g).
The SAMP8 mice fed normal chow (P8 + N) group had hair loss
t the time of assessment, whereas the SAMP8 mice administered
JG (P8 + GJG) group had reduced hair loss (data not shown). Pho-
ographs of lower extremities are shown in Fig. 2a. Histological anal-
sis of soleus muscles using H&E staining revealed a marked reduc-
ion in muscle ﬁber size in the P8 + N group; however, we observed
hat muscle atrophy was strikingly alleviated in the P8 + GJG group
Fig. 2b). The area of muscle ﬁbers in the P8 + N group was signiﬁ-
antly less than that in the other groups; however, the area of muscle
bers in P8+ GJGwas almost the same as that of the SAMR1mice fed
ormal chow (R + N) and SAMR1mice fed GJG (R + GJG) (p < 0.0001,
ne-way ANOVA) (Fig. 2c).
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Fig. 4. GJG sustained glycogen storage in SAMP8 mice.(a) Serum IGF-1 as determined by ELISA. These data are expressed as means ± SD. ∗p < 0.05 vs. the P8 + N group (one-way
ANOVA). (b through c) Western blotting analysis of soleus muscles. (b) Upper panel shows pAkt (Thr308), middle panel shows pAkt (Ser473), and bottom panel shows Akt. (c)
Upper panel shows p GSK-3β (Ser9) and bottom panel shows GSK-3β . (d) PAS staining of the soleus muscles. The bar indicates 200 μm. Magniﬁcation: 200×. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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in the soleus of SAMP8 mice via expression of peroxisome
proliferator-activated receptor-co-activator 1α (PGC-1α)
Immunohistochemical analysis showed that the level of SERCA1
(fast skeletal muscle) was lower in the P8+N group than in the other
groups. However, the P8 + GJG group ameliorated the increase in
slow skeletal muscle ﬁbers (Fig. 3a and B). Western blotting analy-
sis revealed that the expression of troponin I (slow skeletal muscle)
increased in the P8 + N group, whereas it was suppressed in the
P8 + GJG group. As compared with mice of the P8 + N group, mice of
the P8 + GJG group demonstrated increased expression of troponin T
(fast skeletal muscle; Fig. 3c). Muscle ﬁber type determination is reg-
ulated by PGC-1α (Lin et al. 2002) which is phosphorylated by AMPK
(Jager et al. 2007). Fig. 3c also shows that the expression of themn the P8 + N group was lower than in the control groups (R + N,
+ GJG). However, in the P8 + GJG group, the expression of p-AMPK
nd PGC-1α was normal.
JG elevated serum IGF-1 and maintained glycogen storage via
hosphorylation of Akt and GSK-3β in the soleus of SAMP8 mice
Fig. 4a shows that the administration of GJG elevated the levels of
erum IGF-1 in SAMP8 mice. Next, we examined signaling in skeletal
uscles via western blotting. Akt is activated by phosphorylation of
hreonine 308 (Thr308) and of serine 473 (Ser473) (Sarbassov et al.
005). Fig. 4b shows that phosphorylation of Akt, especially at Thr308,
as signiﬁcantly decreased in the muscles of P8 + N mice. This
rend was corrected by the administration of GJG. Fig. 4c shows the
hosphorylation levels of GSK-3β in the skeletal muscles of mice.
Y. Kishida et al. / Phytomedicine 22 (2015) 16–22 21
Fig. 5. GJG decreased the expression of MuRF1 via normalization of FoxO4 phosphorylation levels and TNF-α in SAMP8 mice, and schema of the signaling pathways involved in
skeletal muscles of mice administered GJG. (a through b)Western blotting analysis of soleusmuscles. (a) Upper panel shows pFoxO4 and bottom panel shows FoxO4. (b) Expression
of MAFbx, MuRF1, and TNF-α. GAPDH is shown as a loading control. (c) Schema for the effect of GJG on skeletal muscle.
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ahe levels of p-GSK-3β were lower in P8 + N than in the other
roups,whereas treatmentwithGJG improved the levels of p-GSK-3β
Fig. 4c). Next, we evaluated the glycogen content in skeletal muscle
y using PAS staining. Fig. 4d shows that the deep red regions (indi-
ating a high glycogen content) of the soleus in the P8+N groupwere
uch smaller than those of the other groups; however, the deep red
egions of the soleus in the P8 + GJG group were markedly larger.
JG reduced the expression of MuRF1 via normalization of FoxO4
hosphorylation levels in the soleus of SAMP8 mice
TheAkt-axis stimulates phosphorylationof the FoxO family,which
egulates the expression levels of atrogin-1/MAFbx and MuRF1,
hereby suppressing the degradation of protein in skeletal muscle
Brunet et al. 1999; Franke et al. 1997). In our study, phosphorylation
f FoxO4markedly decreased in the P8+Ngroup, and administration
f GJG to mice did not reduce these phosphorylation levels (Fig. 5a).
e evaluated the expression of phosphorylation of FoxO1 and FoxO3,
nd they were slightly suppressed in SAMP8 mice (data not shown).
ig. 5b shows that the expression levels of atrogin-1/MAFbx were
naffected regardless of whether GJG was administered. However,
uRF1 expression levels were suppressed by GJG in SAMP8 mice.
s TNF-α reportedly reduces PGC-1α expression and induces MuRF1
xpression (Cai et al. 2004; Remels et al. 2010), we evaluated the
xpression of TNF-α in soleus muscles. Fig. 5b also shows that the ex-
ression levels of TNF-α were elevated in the P8 + N group, whereas
dministration of GJG to mice suppressed its level.iscussion
In this study,wedemonstrated thatGJGprevented theprogression
f sarcopenia in SAMP8 mice. In addition, we showed that adminis-
ration of GJG to SAMP8 mice maintained the area of muscle ﬁbers
n the soleus via normalizing signal transduction through the IGF-1-
kt axis, the suppression of inﬂammation, and the maintenance of
itochondrial-related transcription factors. We found that skeletal
uscles in SAMP8 mice treated with GJG were comprised of more
ast skeletal muscle ﬁbers as compared to the P8+N group. Themus-
le ﬁber type has been reported to be regulated by PGC-1α (Lin et al.
002); this protein is known to play an important role in activating
itochondrial biogenesis and oxidative metabolism (Wu et al. 1999).
n the present study, the expression level of PGC-1α decreased in
AMP8 mice; however, administration of GJG changed this trend.
Mitochondrial turnover changes with aging, and autophagy is se-
uentially decreased in atrophying muscles (Romanello et al. 2010).
GC-1α is phosphorylated by AMPK (Jager et al. 2007). Koltai et al.
eported that phosphorylated AMPK content decreases with aging
Koltai et al. 2012). Our study did not contradict their results. It is
ell known that IGF-1 is essential for growth and the promotion
f skeletal muscle development (Brunet et al. 1999; Franke et al.
997). Moreover, an age-related reduction in plasma IGF-1 concen-
rations is well known (Donahue et al. 1990). We showed that ad-
inistration of GJG elevated serum levels of IGF-1 in SAMP8 mice.
ur study also demonstrated that phosphorylation of Akt at Thr308
nd Ser473 signiﬁcantly declined in the muscles of SAMP8 mice,
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phosphorylation of Akt in SAMP8mice to that seen in SAMR1mice. It
is possible that the Akt in the skeletal muscles of P8 + GJG mice was
activated mainly by phosphorylation at Thr308.
In skeletal muscles, Akt stimulates glycogen synthesis via phos-
phorylation of GSK-3β and inhibits protein degradation via phos-
phorylation of FoxOs (Brunet et al. 1999; Franke et al. 1997). GJG
treatment restored the phosphorylation of GSK-3β levels in SAMP8
mice to those seen in SAMR1 mice. The present study showed that
the PAS staining density of GJG-treated SAMP8micewas signiﬁcantly
higher than that of SAMP8 mice fed with normal chow. Our ﬁndings
suggested that GJG sustained glycogen storage in the skeletal mus-
cles of SAMP8mice by changing the phosphorylation levels of Akt and
GSK-3β .
Next, we examined the phosphorylation levels of FoxOs, which
are associated with skeletal muscle atrophy and is inactivated by Akt
(Brunet et al. 1999; Franke et al. 1997). It has been reported that the
regulation of FoxO1 and FoxO3 is different from that of FoxO4 (Senf
et al. 2011). In the present study, phosphorylations of FoxO1 and
FoxO3 were slightly suppressed in SAMP8 mice; however, a marked
reduction in phosphorylation of FoxO4was observed, and these levels
recovered with GJG treatment. FoxOs regulate the expression levels
of atrogin-1/MAFbx and MuRF1, which are up-regulated in atrophic
and aged skeletal muscles (Brunet et al. 1999; Franke et al. 1997).
The present study showed that the expression level of MuRF1 in the
P8 + N group was higher than that in P8 + GJG, but no similar trend
was observed for atrogin-1/MAFbx. On the other hand, Yoshida et al.
suggested that FoxO1 does not activate transcription of MuRF1, but
does activate that of atrogin-1/MAFbx (Yoshida et al. 2010). Cai et
al. reported that TNF-α upregulates the expression of MuRF1 but not
of MAFbx (Cai et al. 2004). In our study, although the expression of
TNF-α was high in SAMP8 mice, it was suppressed by GJG. Our data
thus do not contradict these previous studies.
In conclusion, we showed that GJG suppressed sarcopenia via the
IGF-1/insulin pathway, maintained the expression of mitochondrial-
related transcription factors, and suppressed TNF-α in SAMP8 mice
(see Fig. 5c for a summary). Our results indicate thatGJG is a promising
candidate for relief from sarcopenia.
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